Cargando…

The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study

Ninety-four common genetic variants are confirmed to be associated with breast cancer. This study tested the hypothesis that breast cancer susceptibility variants may also be associated with chemotherapy-induced toxicity through shared mechanistic pathways such as DNA damage response, an association...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dorling, Leila, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938564/ https://www.ncbi.nlm.nih.gov/pubmed/27392074 http://dx.doi.org/10.1371/journal.pone.0158984

Ejemplares similares

A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities
por: Abraham, Jean E., et al.
Publicado: (2015)

Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?
por: Earl, Helena, et al.
Publicado: (2015)

The challenges of using radiological ‘tumour response' as an outcome: lessons learned from neo-tango and artemis, two neo-adjuvant chemotherapy breast cancer trials
por: Hiller, Louise, et al.
Publicado: (2013)

Optimising patient recall of adverse events over prolonged time periods
por: Hiller, Louise, et al.
Publicado: (2011)

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer
por: Ali, H. Raza, et al.
Publicado: (2016)

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial
por: Provenzano, E, et al.
Publicado: (2013)

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results
por: Hiller, Louise, et al.
Publicado: (2018)

Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping
por: Abraham, Jean E, et al.
Publicado: (2012)

Trastuzumab-associated cardiac events in the Persephone trial
por: Earl, Helena M, et al.
Publicado: (2016)

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
por: Earl, H M, et al.
Publicado: (2012)

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
por: Ali, H. R., et al.
Publicado: (2017)

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen
por: Abraham, Jean E, et al.
Publicado: (2010)

Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls
por: Zanti, Maria, et al.
Publicado: (2023)

Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity
por: Ahmed, Mahbubl, et al.
Publicado: (2016)

Multi-omic machine learning predictor of breast cancer therapy response
por: Sammut, Stephen-John, et al.
Publicado: (2021)

Assessing violations of the proportional hazards assumption in Cox regression: does the chosen method matter?
por: Hiller, Louise, et al.
Publicado: (2015)

Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer
por: Kerns, Sarah L., et al.
Publicado: (2016)

NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life
por: Earl, H M, et al.
Publicado: (2008)

Under-representation of male patients in breast cancer studies
por: Mistry, Pankaj, et al.
Publicado: (2015)

The Toxic Effect of Language on Medicine
por: Pharoah, Paul, et al.
Publicado: (1996)

A Bayesian adaptive design for biomarker trials with linked treatments
por: Wason, James M S, et al.
Publicado: (2015)

Impact of the COVID-19 Pandemic on the Mental Health of Healthcare Workers
por: Chatzittofis, Andreas, et al.
Publicado: (2021)

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
por: Earl, H. M., et al.
Publicado: (2017)

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
por: Earl, Helena M, et al.
Publicado: (2019)

chromMAGMA: regulatory element-centric interrogation of risk variants
por: Nameki, Robbin, et al.
Publicado: (2022)

Common germ-line polymorphism of C1QA and breast cancer survival
por: Azzato, E M, et al.
Publicado: (2010)

Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
por: Pharoah, P D P, et al.
Publicado: (1999)

Novel variants in the ACTA2 and MYH11 genes in a Cypriot family with thoracic aortic aneurysms: a case report
por: Keravnou, Anna, et al.
Publicado: (2018)

The Role of Perceived Organizational Support in Mental Health of Healthcare Workers During the COVID-19 Pandemic: A Cross-Sectional Study
por: Chatzittofis, Andreas, et al.
Publicado: (2021)

Investigation of in-phase bilateral exercise effects on corticospinal plasticity in relapsing remitting multiple sclerosis: A registered report single-case concurrent multiple baseline design across five subjects
por: Sokratous, Dimitris, et al.
Publicado: (2023)

Zebrafish as an Alternative Vertebrate Model for Investigating Developmental Toxicity—The Triadimefon Example
por: Zoupa, Maria, et al.
Publicado: (2017)

tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation
por: Wardley, A M, et al.
Publicado: (2008)

Practicalities of using an adaptive design for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests
por: Dunn, Janet, et al.
Publicado: (2015)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Genetic Susceptibility to Systemic Sclerosis in the Greek-Cypriot Population: A Pilot Study
por: Chairta, Paraskevi, et al.
Publicado: (2020)

Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index
por: McDowell, P. Jane, et al.
Publicado: (2022)

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
por: Callagy, Grace M, et al.
Publicado: (2008)

Nitrofurantoin‐induced acute pulmonary toxicity
por: Livanios, Konstantinos, et al.
Publicado: (2016)

Reliable gene expression profiling of formalin-fixed paraffin-embedded breast cancer tissue (FFPE) using cDNA-mediated annealing, extension, selection, and ligation whole-genome (DASL WG) assay
por: Iddawela, Mahesh, et al.
Publicado: (2016)

Novel Bayes Factors That Capture Expert Uncertainty in Prior Density Specification in Genetic Association Studies
por: Spencer, Amy V., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_50sr0636lfdm7uq5fb75gav40e